Active, not recruitingNCT05503030

Correlation Between Changes in Lung Function and Changes in Cough and Dyspnoea in Nintedanib-treated Connective Tissue Disease Interstitial Lung Disease (CTD-ILD) Patients

Studying Secondary interstitial lung disease in childhood and adulthood associated with a connective tissue disease

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Boehringer Ingelheim
Intervention: Nintedanib(drug)
Enrollment: 88 target
Eligibility: 18 years · All sexes
Timeline: 2022 – 2026

Study locations (17)

Private physician, Athens, Greece
"G. Gennimatas" General Hospital of Athens, Athens, Greece
"Ippokration" General Hospital of Athens, Athens, Greece
"Laiko" General Hospital of Athens, Athens, Greece
"ATTIKON" University General Hospital, Athens, Greece
"KAT" General Hospital, Athens, Greece
University General Hospital of Heraklion, Heraklion, Greece
Private physician, Ioannina, Greece
University General Hospital of Ioannina, Ioannina, Greece
Private physician, Larissa, Greece
University General Hospital of Larisa, Larissa, Greece
Private physician, Nea Smirni, Athens, Greece
Private physician, Pátrai, Greece
University General Hospital of Patra, Pátrai, Greece
Private physician, Thessaloniki, Greece
+2 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05503030 on ClinicalTrials.gov

Other trials for Secondary interstitial lung disease in childhood and adulthood associated with a connective tissue disease

Additional recruiting or active studies for the same condition.

See all trials for Secondary interstitial lung disease in childhood and adulthood associated with a connective tissue disease →

← Back to all trials